Stock code: 688139 Stock abbreviation: Haier Bio Bulletin No.: 2024-038

Qingdao Haier Biomedical Co., Ltd.

Announcement on the progress of the repurchase of the company's shares by means of centralized bidding.

the company's board of directors and all directors to ensure that the contents of this announcement does not exist any false records, misleading statements or major omissions, and the authenticity, accuracy and completeness of the contents of the legal responsibility.

Important Content Tips:

As of May 31, 2024, Qingdao Haier Biomedical Co., Ltd. (hereinafter referred to

"Company") through the Shanghai Stock Exchange trading system to buy back the company's shares by means of centralized bidding transactions.

815,617 shares, representing 0.26 per cent of the Company's total share capital of 317,952,508, were the most repurchased.

The high price is 32.31 yuan/share, the lowest price is 27.40 yuan/share, and the total amount of funds paid is RMB

25,654,978.48 yuan (excluding transaction costs).

Basic information on 1. share repurchases

The company held the 17th meeting of the second board of directors on February 8, 2024, and reviewed and approved

Proposal to Repurchase the Company's Shares by Centralized Auction Transaction (hereinafter referred to as "the Repurchase Party"

case "), agreed to repurchase some of the Company's issued RMB ordinary shares (A shares) with its own funds through the trading system of the Shanghai Stock Exchange by means of centralized bidding. All the repurchased shares will be used for employee stock ownership plan or equity incentive at an appropriate time in the future. The repurchase price shall not exceed 50 yuan/share (inclusive), and the total amount of repurchase funds shall not be less than 25 million yuan (inclusive) or more than 50 million yuan (inclusive). The repurchase period shall be within 12 months from the date when the board of directors of the company deliberates and approves the repurchase plan. For details, please refer to the public

The company will be on the website of Shanghai Stock Exchange on February 9, 2024 and February 20, 2024 respectively.

(www.sse.com.cn) The announcement of Qingdao Haier Biomedical Co., Ltd. on the repurchase of the company's shares by means of centralized bidding and the company's implementation of the action plan of "improving quality and efficiency and re-return" (public.

Report No. 2024-004), "Report on the Repurchase of the Company's Shares by means of Centralized Auction Transaction" (Announcement No. 2024-005).

Basic information on the implementation of share repurchase in 2.

In accordance with the "Share Repurchase Rules for Listed Companies", "Shanghai Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 7-Repurchase of Shares" and other relevant regulations, the company shall announce the progress of the repurchase as of the end of last month within the first 3 trading days of each month. The details of the progress of the Company's share repurchase are hereby announced as follows:

In May 2024, the Company failed to return through the trading system of the Shanghai Stock Exchange by means of centralized bidding.

Purchase of shares. As of May 31, 2024, the company through the Shanghai Stock Exchange trading system to focus on competition.

A total of 815,617 shares of the Company were repurchased by way of price trading, accounting for 317,952,508 shares of the Company's total share capital.

The highest price for a repurchase transaction is $32.31 per share and the lowest price is $27.40 per share.

The total amount of funds is RMB 25,654,978.48 (excluding transaction costs).

The repurchase of shares is in compliance with laws and regulations and the Company's share repurchase program.

3. other matters

The company will strictly follow the "Share Repurchase Rules for Listed Companies", "Shanghai Stock Exchange Listed Companies Self-Regulatory Guidelines No. 7-Share Repurchase" and other relevant regulations and the company's share repurchase plan, and choose opportunities according to market conditions during the repurchase period Make repurchase decisions and implement them, and at the same time perform information disclosure obligations in a timely manner based on the progress of the repurchase of shares. Investors are kindly requested to pay attention to investment risks.

It is hereby announced.

Board of Directors of Qingdao Haier Biomedical Co., Ltd.

June 4, 2024